Diarrhea  >>  Ibodutant (MEN 15596)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ibodutant (MEN 15596) / Menarini
IRIS-3, NCT02107196 / 2013-000894-56: 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Completed
3
535
US, Europe, RoW
Ibodutant 10 mg, Code: MEN 15596, Placebo, Sugar pill
Menarini Group
Irritable Bowel Syndrome With Diarrhea
06/15
06/15
IRIS-4, NCT02120027 / 2013-000895-14: 52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Terminated
3
558
US, Europe
Ibodutant 10 mg, Code: MEN 15596, Placebo, Sugar pill
Menarini Group
Irritable Bowel Syndrome With Diarrhea
11/15
11/15
IRIS-05, NCT02320318: 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Withdrawn
3
0
RoW
Ibodutant 10 mg, MEN 15596, Placebo, Sugar pill
Menarini Group
Irritable Bowel Syndrome With Diarrhea
12/16
12/16

Download Options